PDCD1 and neoplasm: Nonetheless, given its biofunction against PD-L1, exosomal PD-1, in cooperation with other exosomal ICP receptors, could still possibly be applied as one of a group of comprehensive tumor prognostic markers in future investigations with clinical samples.